Thomas Flaten: Great. Appreciate it. Thanks guys.
Operator: Thank you. Our next question comes from the line of Robert Hazlett with BTIG. Your line is now open.
Robert Hazlett: Thanks. Congrats on the progress, and I have a couple for me. Just, I know you are not forecasting any price increases, Adam. But what was the price increase around year-end? Sorry, how did you say how much that was?
Jim Fong: Hi, Bert, this is Jim Fong. Yes, it was approximately 9.9% on January 3rd.
Robert Hazlett: Okay. Great. Thank you. And then just with regard to the anemia data is there kind of a broader strategy with regard to NCCN guidelines or additional publication that we should be thinking about as we think about kind of the evolution of VONJO?
Adam Craig: Yes, certainly. We’ve already submitted some anemia data to NCCN and it’s actually under review, but the final data set from Stephen’s work will be submitted once the latest version are published. We’re waiting for publication or based on data we submitted last year, once it’s published, we can then submit the additional data. And we do expect there to be a modification of the guidelines sometime around midyear with the potential approval of momelotinib.
Robert Hazlett: Okay. Terrific. Is there a digital IP that’s available with regard to anemia for VONJO?
Adam Craig: I doubt it, the composition of matter IP is pretty robust and with the five year patent term extension that will take us 2034 . I doubt the anemia data will be €“ will provide anything. It would have to €“ for additional patent protection or patent filing, we’d have to something that was novel and it’s probably wouldn’t be considered as such.
Robert Hazlett: Okay. Terrific. Just one more for me. There’s a material jump in prescriptions and in various metrics. I know that is a hugely blunt instrument, especially with regard to products like VONJO, but we saw a jump in the January data. Are there €“ is there anything behind that? Just would like to maybe know a little bit more? Or is that the anemia data kicking in or other things at work there? Thanks.
Jim Fong: Yes Bert, what are you €“ what data are you referring to? Do you have a different syndicated report?
Robert Hazlett: The symphony data, there is various prescription data, manufacturing benchmark sales, different data metrics like that show a pretty material jump. And I just want to make sure I understand some of the elements behind that.
Jim Fong: Yes, Bert, as you’ve seen, obviously, the momentum that was created in Q4 ahead of Q1 is really continuing. And I think the €“ so we had already, again, seen robust momentum already started by the end of the year as the messages started to really penetrate our target audience. But I think the oral presentation at ASH; no doubt continue to fuel that momentum that we’re seeing today in Q1.
Robert Hazlett: Okay, thanks very much.
Adam Craig: Thank you, Bert.
Operator: Thank you. This concludes the question-and-answer session. I’d now like to hand the conference back over to Adam Craig for closing remarks.
Adam Craig: Thank you, Shannon. And thank you everyone, for joining the call today. We appreciate your continued interest in CTI, and we look forward to keeping you updated on our progress. Shannon, that now concludes the call.
Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.
